- Corporate Officers - C
- Collard Craig A
Insider Trading History of Collard Craig A
The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Collard Craig A since 2021.
This trader's CIK number is 1363558.
At the time of last reporting, Collard Craig A was the Chief Executive Officer of Heron Therapeutics, Inc. /de/. (stock ticker symbol HRTX).
Also see all insider trading activities at Heron Therapeutics, Inc. /de/.
Note that in the past
Collard Craig A also reported insider trading activities as an insider of the following companies:
Yearly summary of insider trading at Sierra Oncology, Inc. (SRRA) by Collard Craig A
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2021 | SRRA | 13,500 | $310,862 | 0 | $0 | 0 | $0 |
Yearly summary of insider trading at Opiant Pharmaceuticals, Inc. (OPNT) by Collard Craig A
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2022 | OPNT | 36,539 | $469,573 | 0 | $0 | 0 | $0 |
| 2021 | OPNT | 12,077 | $219,434 | 0 | $0 | 0 | $0 |
Yearly summary of insider trading at Heron Therapeutics, Inc. /de/ (HRTX) by Collard Craig A
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2025 | HRTX | 0 | $0 | 0 | $0 | 173,468 | $0 |
| 2024 | HRTX | 0 | $0 | 0 | $0 | 103,891 | $0 |
| 2023 | HRTX | 150,000 | $138,000 | 0 | $0 | 0 | $0 |
Yearly summary of insider trading at Terrascend Corp. (TRSSF) by Collard Craig A
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2022 | TRSSF | 180,000 | $0 | 0 | $0 | 0 | $0 |
Insider trading activities at 4 companies by Collard Craig A:
1. Sierra Oncology, Inc. (SRRA)
2. Opiant Pharmaceuticals, Inc. (OPNT)
3. Heron Therapeutics, Inc. /de/ (HRTX)
4. Terrascend Corp. (TRSSF)
Table 1. Insider trading of Sierra Oncology, Inc. (SRRA) by Collard Craig A
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2021-11-23 | SRRA | Buy | 5,601 | 22.95 | 128,514 |
| 2021-11-24 | SRRA | Buy | 7,899 | 23.09 | 182,348 |
Table 2. Insider trading of Opiant Pharmaceuticals, Inc. (OPNT) by Collard Craig A
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2022-06-10 | OPNT | Buy | 1,663 | 11.50 | 19,117 |
| 2022-06-13 | OPNT | Buy | 4,037 | 10.94 | 44,148 |
| 2022-05-16 | OPNT | Buy | 27,150 | 13.54 | 367,611 |
| 2022-05-13 | OPNT | Buy | 3,689 | 10.49 | 38,697 |
| 2021-09-13 | OPNT | Buy | 2,500 | 18.13 | 45,325 |
| 2021-09-10 | OPNT | Buy | 9,577 | 18.18 | 174,109 |
Table 3. Insider trading of Heron Therapeutics, Inc. /de/ (HRTX) by Collard Craig A
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2025-07-31 | HRTX | Option Ex | 34,789 | .00 | 0 |
| 2025-07-19 | HRTX | Option Ex | 13,797 | .00 | 0 |
| 2025-04-30 | HRTX | Option Ex | 34,789 | .00 | 0 |
| 2025-04-19 | HRTX | Option Ex | 13,796 | .00 | 0 |
| 2025-04-03 | HRTX | Option Ex | 62,500 | .00 | 0 |
| 2025-01-19 | HRTX | Option Ex | 13,797 | .00 | 0 |
| 2024-10-19 | HRTX | Option Ex | 13,797 | .00 | 0 |
| 2024-07-19 | HRTX | Option Ex | 13,797 | .00 | 0 |
| 2024-04-19 | HRTX | Option Ex | 13,797 | .00 | 0 |
| 2024-04-03 | HRTX | Option Ex | 62,500 | .00 | 0 |
| 2023-11-16 | HRTX | Buy | 150,000 | .92 | 138,000 |
Table 4. Insider trading of Terrascend Corp. (TRSSF) by Collard Craig A
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2022-09-23 | TRSSF | Buy | 60,000 | .00 | 0 |
| 2022-09-22 | TRSSF | Buy | 120,000 | .00 | 0 |
Insider trading activities including stock purchases, stock sales, and option exercises
listed in the above table cannot be completely guaranteed as to their accuracy.
For more information regarding the trades made by Collard Craig A
(Chief Executive Officer of Heron Therapeutics, Inc. /de/ at the time of this reporting) see
the Securities and Exchange Commission (SEC) website.